These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 14631239)
21. Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis. Cheng CQ; Xu H; Liu L; Wang RN; Liu YT; Li J; Zhou XK J Am Dent Assoc; 2016 Apr; 147(4):236-43. PubMed ID: 26563850 [TBL] [Abstract][Full Text] [Related]
22. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. Scarantino C; LeVeque F; Swann RS; White R; Schulsinger A; Hodson DI; Meredith R; Foote R; Brachman D; Lee N J Support Oncol; 2006 May; 4(5):252-8. PubMed ID: 16724649 [TBL] [Abstract][Full Text] [Related]
23. [Results of the treatment with oral pilocarpine in 100 patients with primary Sjögrens syndrome]. Brito-Zerón P; Ramos-Casals M; Nardi N; Font J Med Clin (Barc); 2006 Apr; 126(16):637. PubMed ID: 16759558 [No Abstract] [Full Text] [Related]
24. [Pharmacological and clinical profile of pilocarpine hydrochloride (SALAGEN) Tab. 5 mg)]. Maruyama K; Koshihara N Nihon Yakurigaku Zasshi; 2006 May; 127(5):399-407. PubMed ID: 16819247 [No Abstract] [Full Text] [Related]
25. Low-dose Pilocarpine Spray to Treat Xerostomia. Zur E Int J Pharm Compd; 2020; 24(2):104-108. PubMed ID: 32196472 [TBL] [Abstract][Full Text] [Related]
26. Assessment of the use of sialogogues in the clinical management of patients with xerostomia. Chainani-Wu N; Gorsky M; Mayer P; Bostrom A; Epstein JB; Silverman S Spec Care Dentist; 2006; 26(4):164-70. PubMed ID: 16927740 [TBL] [Abstract][Full Text] [Related]
27. Drug used during radiotherapy helps reduce dry mouth problem. Expert Rev Anticancer Ther; 2001 Jun; 1(1):4. PubMed ID: 12113130 [No Abstract] [Full Text] [Related]
28. Pilocarpine for the treatment of refractory dry mouth (xerostomia) associated with botulinum toxin type B. Dave SJ Am J Phys Med Rehabil; 2008 Aug; 87(8):684-6. PubMed ID: 18645325 [TBL] [Abstract][Full Text] [Related]
34. Decreased salivary flow rate as a dipsogenic factor in hemodialysis patients: evidence from an observational study and a pilocarpine clinical trial. Sung JM; Kuo SC; Guo HR; Chuang SF; Lee SY; Huang JJ J Am Soc Nephrol; 2005 Nov; 16(11):3418-29. PubMed ID: 16177001 [TBL] [Abstract][Full Text] [Related]
35. Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. Aframian DJ; Helcer M; Livni D; Markitziu A Oral Dis; 2006 May; 12(3):297-300. PubMed ID: 16700739 [TBL] [Abstract][Full Text] [Related]
37. Pilocarpine toxicity and the treatment of xerostomia. Hendrickson RG; Morocco AP; Greenberg MI J Emerg Med; 2004 May; 26(4):429-32. PubMed ID: 15093850 [TBL] [Abstract][Full Text] [Related]
38. Vitreofoveal traction associated with the use of pilocarpine to reverse mydriasis. Walker JD; Alvarez MM Eye (Lond); 2007 Nov; 21(11):1430-1. PubMed ID: 17948034 [No Abstract] [Full Text] [Related]
39. Xerostomia. Absence makes the mouth get drier. Harv Health Lett; 2000 May; 25(7):7. PubMed ID: 10760968 [No Abstract] [Full Text] [Related]
40. Mutans streptococci in xerostomic cancer patients after pilocarpine therapy: a pilot study. Chambers MS; Keene HJ; Toth BB; Lemon JC; Gallagher SC; Martin CG; Martin JW Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Feb; 99(2):180-4. PubMed ID: 15660089 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]